Loading…
Large Chinese manufacturer of bulk pharmaceutical chemicals (APIs) and finished generic drugs, notably pain relievers and antibiotics.
Large Chinese manufacturer of bulk pharmaceutical chemicals (APIs) and finished generic drugs, notably pain relievers and antibiotics.
Sells bulk pharmaceutical chemicals to generic-drug makers at prices that follow supply and demand for each compound, so margins swing with raw-material costs and competing producers. It also sells finished generic drugs to Chinese hospitals and pharmacies. The Hong Kong H share is a second listing of the same company as the Shenzhen-listed A share.
In one line: A Chinese bulk-API generics maker.
Moat: narrow (scale, cost advantage). Large-scale, low-cost bulk chemical production built over decades of state-backed operation.
Headquarters: Zibo, China · Founded: 1943 · Employees: 7,240
Size Shandong Xinhua Pharmaceutical (0719.HK) is a Hong Kong Health Care company (Pharmaceuticals: Other) with a market value of $1.09B, the 574th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$5.47 on 6 Nov 2026.
Performance Over six months the shares fell 11.3%, against -15.6% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue fell 0.5% over the last twelve months (peer median +5.4%); the operating margin is 3.6% (peer median 15.4%).
Valuation It trades at 6.8× forward earnings against a peer median of 19.9× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.7 points above its cost of capital (6.8% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$9.13B | HK$9.46B | HK$9.18B | HK$8.85B | HK$8.65B |
| Revenue growth | — | +3% | +4% | +2% | — |
| Gross profit | HK$2.06B | HK$1.58B | HK$2.06B | HK$2.44B | HK$2.19B |
| EBITDA | n/a | HK$1.03B | HK$1.14B | HK$1.14B | HK$1.11B |
| Net income | HK$260M | HK$314M | HK$510M | HK$549M | HK$478M |
| Free cash flow | HK$359M | HK$464M | HK$177M | -HK$57.1M | HK$606M |
| Capital expenditure | HK$96.0M | HK$125M | HK$230M | HK$359M | HK$285M |
| Total debt | HK$2.05B | HK$2.26B | HK$2.28B | HK$2.06B | HK$2.12B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shandong Xinhua Pharmaceutical 0719.HK | $1.09B | -11% | -1% | 4% | 6.8× | -2.0% |
| United Laboratories International 3933.HK | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% |
| North China Pharmaceutical 600812.SS | $1.17B | -8% | -21% | 5% | n/a | 1.4% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0719.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.7% | -2.2% | 7th lowest of 21 |
| 6-month return | -11.3% | -15.6% | 8th highest of 21 |
| Distance from 52-week high | -28.3% | -31.8% | 9th highest of 21 |
| Revenue growth (TTM) | -0.5% | +5.4% | 10th lowest of 21 |
| Operating margin | 3.6% | 15.4% | 4th lowest of 20 |
| Forward P/E | 6.8× | 19.9× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -2.0% | 4.0% | 3rd least demanding of 16 |
| Growth delivered (Del g) | +7.1% | +13.5% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | -9.1 pp | -8.5 pp | 8th least demanding of 16 |
| ROIC minus cost of capital | +2.7 pp | +2.7 pp | 10th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.09B | -11% | -1% | 4% | 6.8× | -2.0% | +7.1% |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 29.6× | 4.0% | +18.5% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | n/a | 3.6% | -1.3% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 16.9× | 14.7% | +15.6% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | n/a | 1.8% | +4.8% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | n/a | -1.1% | +10.4% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | 7.2× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | n/a | 4.9% | +13.5% |